# Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

> **NCT00725764** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 14 (actual)

## Conditions studied

- Neoplasms, Head and Neck

## Interventions

- **DRUG:** GSK1363089 (foretinib)

## Key facts

- **NCT ID:** NCT00725764
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-27
- **Primary completion:** 2009-05-02
- **Final completion:** 2009-05-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725764, "Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00725764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*